🚨 New discovery alert! 🚨
In this month’s issue of @NatureCVR, we identify a dendritic cell population that acts as a hub for immune checkpoint communication within human atherosclerotic plaques. @NYULHCVRC@ChiaraGiannare1rdcu.be/d1S6b
FASCIN1 DCs in mouse and human plaques are a key target of immunotherapies linked to accelerated atherosclerotic plaque progression and increased risk of stroke and myocardial infarction in cancer survivors. #CardioOncology
So fun to collaborate with @GiannarelliL on this! This discovery opens new possibilities for understanding cardiovascular risks in cancer survivors and the role of immune checkpoints in atherosclerosis 🎯 @ICOSociety@CardioOncology
Thrilled to see the outstanding contributions of the 2 recipients of the @InstitutFrance Grand Prix Scientifique Lefoulon Delalande — one of the 🌎 most important prizes in #CardiovascularResearch. So proud to see 🇨🇦 scientist @KathrynMooreLab up there!
Big day for MooreLab at #VascularDiscovery24! @FazliBozal is competing for the Investigator in Training Award & @aacnewman13 for Emerging Scientist Award for Women Award. 🤞
Beyond excited that @KateyRayner was appointed to be the next CSO of the @HeartInstitute! In addition to being a stellar scientist, a tremendous colleague & leader in cardiovascular research, this is also a historical moment b/c she will be the first woman CSO at our institute!
Following a rigorous international recruitment process, the University of Ottawa Heart Institute has named Dr. Katey Rayner as its next chief scientific officer and vice-president of research. Congratulations!
ow.ly/vue050Rcg9g@KateyRayner#ottnews
Using mouse models of Irg1 deficiency, we show that loss of this pathways aggravates atherosclerosis, increasing plaque size, macrophage content, and inflammatory signaling including IL-1b (2/5)
Treatment of mice with advanced atherosclerosis using an itaconate derivative, 4-OI, led to beneficial plaque remodeling, highlighting its potential as a novel therapeutic strategy (4/5)
We show that the enzyme IRG1/ACOD1, responsible for producing the immunomodulatory metabolite itaconate, is expressed in human and mouse atherosclerotic plaques. Intriguingly, its expression decreases with disease progression suggesting loss of this protective mechanism (1/5)